SCHEMBL23069130

SCHEMBL23069130

CC(C)N(C)CCc1c[nH]c2cc3c(cc12)OCO3

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 10/20 0.75
HTR2C P28335 9/20 0.75
HTR1A P08908 9/20 0.75
HTR2A P28223 9/20 0.75
HTR1B P28222 8/20 0.75
HTR2B P41595 7/20 0.75
HTR6 P50406 6/20 0.75
HTR3E A5X5Y0 5/20 0.75
HTR3B O95264 5/20 0.75
HTR1E P28566 5/20 0.75
HTR1F P30939 5/20 0.75
HTR7 P34969 5/20 0.75
HTR3A P46098 5/20 0.75
HTR5A P47898 5/20 0.75
HTR4 Q13639 5/20 0.75
HTR3D Q70Z44 5/20 0.75
HTR3C Q8WXA8 5/20 0.75
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29633043 0.88 HTR1D (0.72) HTR1DHTR2CHTR1AHTR2AHTR1B
SCHEMBL20970979 0.88 HTR1D (0.72) HTR1DHTR2CHTR1AHTR2AHTR1B
SCHEMBL20970981 0.86 HTR1D (1.00) HTR1DHTR2CHTR1AHTR2AHTR1B
SCHEMBL30249043 0.86 HTR1D (1.00) HTR1DHTR2CHTR1AHTR2AHTR1B
SCHEMBL20970917 0.85 HTR1D (0.69) HTR1DHTR2CHTR1AHTR2AHTR1B
SCHEMBL30249112 0.85 HTR1D (0.69) HTR1DHTR2CHTR1AHTR2AHTR1B
SCHEMBL2409566 0.80 HTR1D (0.73) HTR1DHTR2CHTR1AHTR2AHTR1B
SCHEMBL30483763 0.79 HTR1A (0.56) HTR1DHTR2CHTR1AHTR2AHTR1B
SCHEMBL30483762 0.79 HTR1A (0.56) HTR1DHTR2CHTR1AHTR2AHTR1B
SCHEMBL25423326 0.79 HTR1A (0.56) HTR1DHTR2CHTR1AHTR2AHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547250-A1 METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS Terran Biosciences Inc. (US) 2025-05-07 EP claimed
US-20240197681-A1 METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-20 US claimed
EP-4313030-A1 METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS Terran Biosciences, Inc. (US) 2024-02-07 EP claimed
WO-2024006984-A1 METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS TERRAN BIOSCIENCES INC. (US) 2024-01-04 WO claimed
WO-2022212854-A1 METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS TERRAN BIOSCIENCES INC. (US) 2022-10-06 WO claimed
US-20260108544-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2026-04-23 US disclosed
EP-4720030-A1 ASYMMETRIC PHENYLALKYLAMINES Alexander Shulgin Research Institute, Inc. (US) 2026-04-08 EP disclosed
US-20260048048-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2026-02-19 US disclosed
EP-4673127-A1 DEUTERATED AND FLUORINATED EMPATHOGENS Alexander Shulgin Research Institute, Inc. (US) 2026-01-07 EP disclosed
EP-4673430-A2 PHENYLALKYLAMINE PRODRUGS Alexander Shulgin Research Institute, Inc. (US) 2026-01-07 EP disclosed
US-20250325533-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2025-10-23 US disclosed
EP-4618981-A1 COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE Remedi, Inc. (US) 2025-09-24 EP disclosed
WO-2022115798-A2 COMPOSITIONS AND METHODS FOR TREATING MIGRAINE WESANA HEALTH INC. (US) 2022-06-02 WO disclosed
WO-2022115796-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS WESANA HEALTH INC. (US) 2022-06-02 WO disclosed
US-20220160737-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2022-05-26 US disclosed
US-20220125809-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH STAMETS PAUL EDWARD (US) 2022-04-28 US disclosed
US-20210251976-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2021-08-19 US disclosed
WO-2021101926-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH STAMETS PAUL EDWARD (US) 2021-05-27 WO disclosed
US-20210145851-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS, LLC 2021-05-20 US disclosed
US-20210069170-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS, LLC 2021-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210251976-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR1D 15/4885HTR2C 6/4885HTR1A 13/4885
US-20210145851-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR1D 15/4885HTR2C 6/4885HTR1A 13/4885
US-20240197681-A1 METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS HTR1A, HTR2A, HTR3A HTR1D 12/4885HTR2C 5/4885HTR1A 1/4885
US-20260048048-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR1D 13/4885HTR2C 4/4885HTR1A 12/4885
US-20220160737-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR1D 15/4885HTR2C 6/4885HTR1A 13/4885
US-20250325533-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, BDNF, HTR6 HTR1D 14/4885HTR2C 7/4885HTR1A 15/4885
US-20210069170-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR1D 15/4885HTR2C 6/4885HTR1A 13/4885
US-20220125809-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR1D 15/4885HTR2C 6/4885HTR1A 13/4885
US-20260108544-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR1D 7/4885HTR2C 5/4885HTR1A 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.